Whole genome association studies in search of treatment response markers in the patients with chronic genotype 1 hepatitis C virus infection Krzysztof Domagalski, Andrzej Tretyn, Małgorzata Pawłowska, Waldemar Halota Medical Science Review - Hepatologia 2010; 10 73-76 aaICID: 911690
Article type: Review article
IC™ Value: 3.34
Abstract provided by Publisher
In the world 170 millions of people are infected with hepatitis C virus (HCV). Current recommended therapy for chronic HCV infection is expensive, can have serious adverse reactions and is unsuccessful in 50 % of genotype 1 cases. At present is not possible to identify individuals who fail to clear the virus on therapy (nonresponders). Both viral and host factors have been implicated in treatment outcome. Here we review recent progress made in the identification of the host determinants associated with HCV treatment response, using genomewide association studies (GWAS). GWA studies have provided evidence that several SNPs from the region IL-28B gene are significantly associated with response to standard of care therapy.